To discover the IDO1 and HDAC dual inhibitors for cancer treatment by taking advantages of immunotherapeutic and epigenetic drugs, saprorthoquinone was chosen as a hit compound through a pharmacophore fusion strategy. The gene discussed is IDO1; the disease is cancer.